Review
doi: 10.1016/j.mcna.2012.12.012.
Epub 2013 Feb 1.
The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease
Affiliations
- PMID: 23642576
- DOI: 10.1016/j.mcna.2012.12.012
Item in Clipboard
Review
The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease
Med Clin North Am.
2013 May.
Abstract
This article gives an updated account of the clinical application of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease (AD). The clinically most relevant biomarkers, total tau, phospho-tau and Aβ42 are discussed, and how they may be used, together with other diagnostic investigations, to make a predementia diagnosis of AD. Recent findings in sporadic and genetic preclinical AD are also discussed and, more specifically, what the biomarkers have taught us on the sequence of events in the pathogenic process underlying AD.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060. JAMA Psychiatry. 2014. PMID: 25162367
-
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155. Arch Gen Psychiatry. 2012. PMID: 22213792
-
The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.J Intern Med. 2014 Apr;275(4):418-27. doi: 10.1111/joim.12164. Epub 2013 Dec 11. J Intern Med. 2014. PMID: 24237038
-
Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.J Lab Autom. 2015 Oct;20(5):589-600. doi: 10.1177/2211068214559979. Epub 2014 Nov 25. J Lab Autom. 2015. PMID: 25424384 Review.
-
The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. doi: 10.2174/1574889811308010006. Recent Pat CNS Drug Discov. 2013. PMID: 23489287 Review.
Cited by
-
Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment.Alzheimers Res Ther. 2024 Jul 30;16(1):171. doi: 10.1186/s13195-024-01542-4. Alzheimers Res Ther. 2024. PMID: 39080778 Free PMC article.
-
A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.Ups J Med Sci. 2023 Nov 28;128. doi: 10.48101/ujms.v128.10316. eCollection 2023. Ups J Med Sci. 2023. PMID: 38084203 Free PMC article. Review.
-
Survey on Acceptance of Passive Technology Monitoring for Early Detection of Cognitive Impairment.Digit Biomark. 2020 Dec 30;5(1):9-15. doi: 10.1159/000512207. eCollection 2021 Jan-Apr. Digit Biomark. 2020. PMID: 33615117 Free PMC article.
-
Plasma Leptin Reflects Progression of Neurofibrillary Pathology in Animal Model of Tauopathy.Cell Mol Neurobiol. 2022 Jan;42(1):125-136. doi: 10.1007/s10571-020-00972-6. Epub 2020 Sep 30. Cell Mol Neurobiol. 2022. PMID: 32997211
-
Increased inflammation in BA21 brain tissue from African Americans with Alzheimer's disease.Metab Brain Dis. 2020 Jan;35(1):121-133. doi: 10.1007/s11011-019-00512-2. Epub 2019 Dec 10. Metab Brain Dis. 2020. PMID: 31823110
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
